X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs VENUS REMEDIES - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA VENUS REMEDIES ASTRAZENECA PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 182.3 -9.4 - View Chart
P/BV x 27.7 0.1 18,987.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
VENUS REMEDIES
Mar-17
ASTRAZENECA PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,285143 899.9%   
Low Rs63465 975.4%   
Sales per share (Unadj.) Rs189.6324.2 58.5%  
Earnings per share (Unadj.) Rs-0.26.4 -3.2%  
Cash flow per share (Unadj.) Rs3.840.6 9.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6366.0 18.8%  
Shares outstanding (eoy) m25.0012.34 202.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.10.3 1,579.1%   
Avg P/E ratio x-4,712.716.2 -29,074.6%  
P/CF ratio (eoy) x249.62.6 9,746.8%  
Price / Book Value ratio x14.00.3 4,923.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9881,282 1,870.9%   
No. of employees `0001.60.9 172.6%   
Total wages/salary Rs m1,605251 639.3%   
Avg. sales/employee Rs Th3,040.24,430.1 68.6%   
Avg. wages/employee Rs Th1,029.2278.0 370.3%   
Avg. net profit/employee Rs Th-3.387.6 -3.7%   
INCOME DATA
Net Sales Rs m4,7404,000 118.5%  
Other income Rs m9223 405.7%   
Total revenues Rs m4,8324,023 120.1%   
Gross profit Rs m-130785 -16.5%  
Depreciation Rs m101422 24.0%   
Interest Rs m0344 0.0%   
Profit before tax Rs m-13942 -329.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5-37 -13.8%   
Profit after tax Rs m-579 -6.4%  
Gross profit margin %-2.719.6 -14.0%  
Effective tax rate %-3.7-87.9 4.2%   
Net profit margin %-0.12.0 -5.4%  
BALANCE SHEET DATA
Current assets Rs m2,7262,606 104.6%   
Current liabilities Rs m2,4351,980 123.0%   
Net working cap to sales %6.115.6 39.3%  
Current ratio x1.11.3 85.1%  
Inventory Days Days74128 57.5%  
Debtors Days Days4143 94.5%  
Net fixed assets Rs m1,0355,353 19.3%   
Share capital Rs m50123 40.5%   
"Free" reserves Rs m9424,393 21.5%   
Net worth Rs m1,7164,516 38.0%   
Long term debt Rs m01,618 0.0%   
Total assets Rs m4,1568,291 50.1%  
Interest coverage xNM1.1-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.5 236.4%   
Return on assets %-0.15.1 -2.4%  
Return on equity %-0.31.8 -16.9%  
Return on capital %06.3 0.0%  
Exports to sales %5.70-   
Imports to sales %6.518.4 35.1%   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306736 41.6%   
Fx inflow Rs m3750-   
Fx outflow Rs m470736 63.9%   
Net fx Rs m-96-736 13.0%   
CASH FLOW
From Operations Rs m-8997 -0.8%  
From Investments Rs m-146-461 31.6%  
From Financial Activity Rs m862-571 -151.0%  
Net Cashflow Rs m709-35 -2,018.5%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 166.7%  
FIIs % 15.7 0.6 2,706.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 66.4 13.7%  
Shareholders   12,856 20,121 63.9%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Nifty Crosses 11,500-Mark; L&T Surges 4% on Buyback News(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.2% while the Hang Seng is up 0.7%.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 20, 2018 10:47 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS